293 related articles for article (PubMed ID: 32201059)
1. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059
[TBL] [Abstract][Full Text] [Related]
2. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
3. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Okita K; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Jan; 39(1):75.e9-75.e16. PubMed ID: 32665123
[TBL] [Abstract][Full Text] [Related]
6. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
7. Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):194.e9-194.e16. PubMed ID: 32943344
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
Matsumoto A; Nakagawa T; Kanatani A; Ikeda M; Kawai T; Miyakawa J; Taguchi S; Naito A; Otsuka M; Nakanishi Y; Suzuki M; Koga F; Nagase Y; Kondo Y; Okaneya T; Tanaka Y; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2018 Feb; 36(2):249-256. PubMed ID: 29185045
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
11. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
[TBL] [Abstract][Full Text] [Related]
12. Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.
Graffeille V; Verhoest G; Gryn A; Kammerer-Jacquet SF; Alimi Q; Beauval JB; Beuzit L; Pradère B; Thoulouzan M; Khene ZE; Guille F; Rioux-Leclercq N; Mathieu R; Gamé X; Bensalah K; Soulié M; Roumiguié M; Peyronnet B
Urol Int; 2022; 106(2):122-129. PubMed ID: 33626547
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
[TBL] [Abstract][Full Text] [Related]
14. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m
Blute ML; Kucherov V; Rushmer TJ; Damodaran S; Shi F; Abel EJ; Jarrard DF; Richards KA; Messing EM; Downs TM
BJU Int; 2017 Sep; 120(3):387-393. PubMed ID: 28464520
[TBL] [Abstract][Full Text] [Related]
15. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
16. Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer.
Gondran-Tellier B; Abdallah R; Sichez PC; Akiki A; Toledano H; Gaillet S; Delaporte V; Karsenty G; Bastide C; Daniel L; Garcia S; Rossi D; Lechevallier E; Boissier R; Baboudjian M
Prog Urol; 2021 May; 31(6):316-323. PubMed ID: 33663939
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
Kobayashi K; Matsuyama H; Oka S; Nakamura K; Misumi T; Hiroyoshi T; Ito H; Isoyama N; Hirata H; Matsumoto H; Shiraishi K
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103294. PubMed ID: 36681259
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
